|
|
Volumn 20, Issue 3, 2012, Pages 471-472
|
|
The need for increased clarity and transparency in the regulatory pathway for gene medicines in the European union
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIPOGENE TIPARVOVEC;
COMPLEMENTARY DNA;
LIPOPROTEIN LIPASE;
CELL THERAPY;
DISEASE COURSE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG LEGISLATION;
DRUG MARKETING;
EDITORIAL;
ENZYME ACTIVITY;
ENZYME DEFICIENCY;
EUROPEAN UNION;
GENE TARGETING;
GENE THERAPY;
GENETICS;
GOVERNMENT;
GOVERNMENT REGULATION;
HYPERLIPOPROTEINEMIA TYPE 1;
LIPOPROTEIN METABOLISM;
MEDICAL DECISION MAKING;
PANCREATITIS;
|
|
EID: 84857726475
PISSN: 15250016
EISSN: 15250024
Source Type: Journal
DOI: 10.1038/mt.2012.14 Document Type: Editorial |
|
Times cited : (9)
|
|
References (0)
|
